Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bongrani

Showing results (61-70 of 67) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 67 results.
Il Farmaco; Edizione Scientifica|September 1, 1988
[Derivatives of pyrimidine 1,2-condensate. IV. Synthesis and pharmacological properties of the N,N-disubstituted 4-amino-2H-pyrido(1,2-a)pyrimidin- 2-ones and 2-amino-4H-pyrido(1,2-a)pyrmidin-4-ones]M Di Braccio, G Roma, M Mazzei, et al.
Pharmacological Research|October 1, 1993
No-mimetic furoxans: arylsulphonylfuroxans and related compoundsR Ferioli, A Fazzini, G C Folco, et al.
Giornale Italiano Di Cardiologia|January 1, 1979
[Availability of volumertric indices detected from angiocardiography. A comparison between three different contrast media in anesthetized dogs (author's transl)]M Di Donato, F Cucchini, G Baldi, et al.
La Clinica Terapeutica|May 15, 1985
[Experimental analysis of the beta-adrenergic stimulating activity of procaterol. Comparison with other beta-adrenergic agonists]E Marmo, S Chieppa, F Rossi, et al.
Journal of Cardiovascular Pharmacology|April 29, 1998
Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusionR Latini, S Masson, G Jeremic, et al.
Journal of Cardiovascular Pharmacology|September 2, 1999
Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusionS Masson, M Masseroli, F Fiordaliso, et al.
Cardiovascular Drugs and Therapy|October 24, 2001
CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overloadS Masson, S Chimenti, M Salio, et al.
Pageof 7

Showing results (61-70 of 67) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 67 results.
Il Farmaco; Edizione Scientifica|September 1, 1988
[Derivatives of pyrimidine 1,2-condensate. IV. Synthesis and pharmacological properties of the N,N-disubstituted 4-amino-2H-pyrido(1,2-a)pyrimidin- 2-ones and 2-amino-4H-pyrido(1,2-a)pyrmidin-4-ones]M Di Braccio, G Roma, M Mazzei, et al.
Pharmacological Research|October 1, 1993
No-mimetic furoxans: arylsulphonylfuroxans and related compoundsR Ferioli, A Fazzini, G C Folco, et al.
Giornale Italiano Di Cardiologia|January 1, 1979
[Availability of volumertric indices detected from angiocardiography. A comparison between three different contrast media in anesthetized dogs (author's transl)]M Di Donato, F Cucchini, G Baldi, et al.
La Clinica Terapeutica|May 15, 1985
[Experimental analysis of the beta-adrenergic stimulating activity of procaterol. Comparison with other beta-adrenergic agonists]E Marmo, S Chieppa, F Rossi, et al.
Journal of Cardiovascular Pharmacology|April 29, 1998
Comparative efficacy of a DA2/alpha2 agonist and a beta-blocker in reducing adrenergic drive and cardiac fibrosis in an experimental model of left ventricular dysfunction after coronary artery occlusionR Latini, S Masson, G Jeremic, et al.
Journal of Cardiovascular Pharmacology|September 2, 1999
Effects of a DA2/alpha2 agonist and a beta1-blocker in combination with an ACE inhibitor on adrenergic activity and left ventricular remodeling in an experimental model of left ventricular dysfunction after coronary artery occlusionS Masson, M Masseroli, F Fiordaliso, et al.
Cardiovascular Drugs and Therapy|October 24, 2001
CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overloadS Masson, S Chimenti, M Salio, et al.
Pageof 7